528 related articles for article (PubMed ID: 26850595)
1. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.
Sun KX; Jiao JW; Chen S; Liu BL; Zhao Y
J Ovarian Res; 2015 Dec; 8():80. PubMed ID: 26626440
[TBL] [Abstract][Full Text] [Related]
4. miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1.
Zhan M; Zhao X; Wang H; Chen W; Xu S; Wang W; Shen H; Huang S; Wang J
Tumour Biol; 2016 Aug; 37(8):10553-62. PubMed ID: 26852750
[TBL] [Abstract][Full Text] [Related]
5. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells.
Yang X; Cai H; Liang Y; Chen L; Wang X; Si R; Qu K; Jiang Z; Ma B; Miao C; Li J; Wang B; Gao P
Oncol Rep; 2015 Apr; 33(4):1723-30. PubMed ID: 25633261
[TBL] [Abstract][Full Text] [Related]
7. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
8. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
Liu Y; Niu Z; Lin X; Tian Y
Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
[TBL] [Abstract][Full Text] [Related]
9. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
[TBL] [Abstract][Full Text] [Related]
10. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
[TBL] [Abstract][Full Text] [Related]
11. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
13. [Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells].
Li ZM; Hu S; Xiao L; Wang J; Cai J; Yu LL; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):372-5. PubMed ID: 20646448
[TBL] [Abstract][Full Text] [Related]
14. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
15. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
16. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
Cheng W; Liu T; Wan X; Gao Y; Wang H
FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
20. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
